[Effectiveness of the combined use of an inactivated vaccine and a proteolysis inhibitor in the prevention of experimental influenza].
The prophylactic effects produced by different types of antiviral preparations, used separately or in combination, in experimental lethal infection induced by influenza virus AO/32 (H0N1) in mice are compared. The use of inactivated vaccine and E-aminocaproic acid (E-ACA), a proteolysis-inhibiting agent, was studied. The qualitative characterization and quantitative evaluation of the anti-influenza effect were carried out by the method of multifactor analysis with the use of a computer after the optimum second-order plan based on the mathematical theory of experiment. This made it possible to determine the best combination of the preparations and their doses, to establish the time of the formation of reliable protection from influenza in mice. The prophylactic effect produced by the use of E-ACA alone and the capacity of this preparation for enhancing the protective action of inactivated influenza vaccine were established. Mathematical analysis revealed the optimum value of the four factors under study: the dose of the vaccine, the dose of E-ACA, the lapse of time between the injection of the preparations and the challenge of the animals, as well as the infective dose of the pathogenic virus. A special experiment made in the study of these data confirmed that the specific formation of a high level of anti-influenza protection in mice can be achieved by the combined use of the vaccine and the inhibitor of proteolysis.
D015119:Aminocaproic Acid / Q000627:therapeutic use; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D004353:Drug Evaluation, Preclinical; D007114:Immunization / Q000379:methods; D007252:Influenza Vaccines / Q000627:therapeutic use*; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000401:mortality / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012107:Research Design; D013997:Time Factors; D014613:Vaccines, Attenuated / Q000627:therapeutic use
D007252:Influenza Vaccines; D011480:Protease Inhibitors; D014613:Vaccines, Attenuated; D015119:Aminocaproic Acid
Effktivnost' sochetannogo primeneniia inaktivirovannoĭ vaktsiny i ingibitora proteoliza v profilaktike éksperimental'nogo grippa.